Tempus AI to Acquire Personalis in $1.5 Billion Deal: AI and Cancer Testing Come Together
Tempus AI has agreed to acquire Personalis in a transaction valued at approximately $1.5 billion, net of Tempus…
Nexentis Technologies Launches AI-Driven Biotech Platform to Accelerate Drug Discovery
Biotechnology and Artificial Intelligence are rapidly transforming the healthcare industry. Taking a significant step in this direction, Nexentis…
































































